Clinical Trials Logo

Helicobacter Pylori Infection clinical trials

View clinical trials related to Helicobacter Pylori Infection.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04025983 Terminated - Clinical trials for Helicobacter Pylori Infection

Effectiveness of GastimunHp Plus in Supporting the Treatment of Peptic Ulcer Disease With Helicobacter Pylori Infection

GasHp
Start date: November 1, 2019
Phase: N/A
Study type: Interventional

Challenges in the treatment of Helicobacter pylori (H. pylori) include increasing antimicrobial resistance and patient's low tolerance to some regimens. Lactobacillus johnsonii (L. johnsonii) and Immunoglobulin Y (IgY) have been shown to decrease the amount and activity of H. pylori in human stomach and can increase patient's tolerance. We conduct a single-center double-masked randomized controlled trial to evaluate the effectiveness of GastimunHp Plus (a product combining L. johnsonii and IgY) in improving the clearance of H. pylori after six to eight weeks of treatment and side effects of H. pylori treatment. H. pylori is tested by C13- or C14-urea breath test.

NCT ID: NCT03925818 Terminated - Clinical trials for Helicobacter Pylori Infection

Low Dose Bismuth Versus Lactobacillus Reuteri for H. Pylori Eradication

LactoBismu
Start date: August 29, 2017
Phase: N/A
Study type: Interventional

This study investigates the efficacy of a b.i.d. quadruple therapy containing Pylera® or L. reuteri for H. pylori infection.

NCT ID: NCT01643785 Terminated - Clinical trials for Helicobacter Pylori Infection

Additive Effect of Endonase on Eradication Rate of Second Line Therapy for HP Infection

Start date: June 2012
Phase: N/A
Study type: Interventional

Endonase, a kind of protease, is known to cause both extensive degradation of mucins and a reduction in mucus viscosity. As part of the search for more effective forms of therapy against H. pylori when it colonizes not only the surface of the surface mucosal cells but also the surface mucous gel layer covering the mucosal surface of the stomach. The investigators decided to investigate whether or not endonase might have additive effect of pronase on the efficacy of the second-line eradication therapy against Helicobacter pylori.

NCT ID: NCT01575899 Terminated - Clinical trials for Helicobacter Pylori Infection

Efficacy of Seven-day Combined Rabeprazole Plus Levofloxacin Plus Augmentin for Eradication of Helicobacter Pylori

Start date: December 2007
Phase: Phase 4
Study type: Interventional

This prospective controlled randomized open-label clinical trial is designed to determine the eradication rate of 7-day levofloxacin, amoxicillin/clavulanate and rabeprazole regimen compared with 7-day standard triple therapy for adults infected with Helicobacter pylori in Eastern Taiwan.

NCT ID: NCT01109381 Terminated - Clinical trials for Helicobacter Pylori Infection

Safety and Efficacy Study of a Non-antibiotic Treatment for the Eradication of Helicobacter Pylori

Start date: May 2010
Phase: Phase 1/Phase 2
Study type: Interventional

At present, triple therapy is recommended by various guidelines for the treatment of Helicobacter pylori (H.pylori) infection. Recent studies have shown increasing resistance of H.pylori to commonly used antibiotics used in triple therapy. This study explores a non-antibiotic treatment regime for H.pylori that uses lauric acid as the primary anti-microbial agent. The study hypothesis is that Lauric acid works synergistically with omeprazole following administration of a mucolytic agent to kill H.pylori topically in the stomach.